To make it clear Orphan designation for PANDAS/PANS is a good thing but a phase 3 (registrational) trial is the next step before a new drug application can be made. If the NDA is accepted then the drug is considered marketable, and a potential PRV comes into play (for sale to another company potentially). (Only applies for the USA and rare diseases)
Funds for a phase 3 are a concern. I am not certain what their commercial strategy is (or if it has been released) as it seems a bit of a mixture of different things. My perception was that the Autism program was the most advanced and management felt that TGA approval was most likely. It would be a smaller market revenue wise, but any income is a good thing.
OD/Rare diseases are where the big bucks are but these economics apply primarily to the US. The cost of these larger scale trails will reduce more funds.
- Forums
- ASX - By Stock
- NTI
- Ann: Phase II/III autism trial shows further benefits
Ann: Phase II/III autism trial shows further benefits, page-16
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
|
|||||
Last
7.1¢ |
Change
-0.005(6.58%) |
Mkt cap ! $72.23M |
Open | High | Low | Value | Volume |
7.6¢ | 7.8¢ | 6.9¢ | $135.0K | 1.833M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27000 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.1¢ | 33439 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 27000 | 0.070 |
2 | 46286 | 0.069 |
2 | 41617 | 0.068 |
1 | 25000 | 0.067 |
4 | 258292 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.071 | 33439 | 1 |
0.073 | 172720 | 1 |
0.075 | 37501 | 3 |
0.076 | 66000 | 1 |
0.077 | 42000 | 1 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online